Vrouyr Bilemjian: I defended my PhD thesis on Exploring Novel Immune Checkpoints for Ovarian Cancer Therapy at the University of Groningen
Vrouyr Bilemjian, Strategy Consultant at Innoplexus, shared a post on LinkedIn:
“Hora Finita!
Recently, I successfully defended my PhD thesis, ‘Exploring Novel Immune Checkpoints and Targeted Delivery Strategies for Ovarian Cancer Therapy,’ at the University of Groningen.
As a Marie Curie Fellow, I had the privilege of working at the University Medical Center Groningen and Surflay Nanotec GmbH in Berlin within the I-DireCT consortium, bridging academia and industry.
During my PhD, I focused on tumor immunology, Immunotherapeutics, and nanotechnology. My work included identifying novel immune checkpoints on tumor-infiltrating lymphocytes (TILs) in ovarian cancer, which can be targeted with bispecific antibodies and fusion proteins, and developing innovative drug delivery systems to precisely target tumor cells.
Grateful to my supervisors for their invaluable guidance, my colleagues for their collaboration and support, and my family for their encouragement throughout this journey. I would also like to thank the opponents for their thoughtful questions and input during the defense.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023